<DOC>
	<DOCNO>NCT00347971</DOCNO>
	<brief_summary>The purpose study evaluate whether recombinant IL-21 use combination rituximab safe patient non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Recombinant Interleukin 21 Combination With Rituxan Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This Phase 1 open-label dose-escalation study rituximab + rIL-21 combination therapy , administer weekly 4 week follow initial treatment one dose rituximab alone patient B-cell non-Hodgkin 's lymphoma ( NHL ) fail prior therapy ( y ) . A standard dose rituximab use . Increasing dose rIL-21 study sequentially different group patient , start 30 Î¼g/kg . Before start treatment rituximab + rIL-21 , patient treat one dose rituximab alone look rituximab infusion-related symptom ( fever , chill , rigor ) . Patients severe infusion-related side effect first dose rituximab go receive IL-21 . Those unacceptable rituximab-related side effect receive intravenous rIL-21 least 60 minute complete rituximab infusion rest weekly dose visit . Patients evaluate safety course study . Disease evaluation ( tumor restaging ) perform 2 week follow completion first 4-week treatment cycle . Patients stable disease good evaluation may go receive second 4-week treatment cycle rituximab + rIL-21 . Patients may study 2 4 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis CD20+ Bcell NHL Disease measurable compute tomography ( CT ) scan Has fail least one prior systemic therapy NHL Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hepatic renal function Adequate bone marrow function Presence acute infection significant systemic illness White blood cell ( WBC ) count &gt; 50,000/mm3 peripheral blood Central nervous system involvement malignancy Previous allogenic transplant autotransplant within 6 month enrollment Other current malignancy know history cancer within 5 year Received systemic corticosteroid , chemotherapy , immunotherapy , biologic therapy , antibody therapy ( e.g. , rituximab ) , radiation therapy , and/or investigational agent ( ) within 1 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>interleukin-21</keyword>
	<keyword>rituximab</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>